Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM0504 in Non-diabetic Overweight or Obese Adult Subjects
NCT07166081Phase 1Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BGM0504 in obesity and Overweight (5 arms), sponsored by BrightGene Bio-Medical Technology. Primary endpoint: Number of treatment adverse events at 11 weeks. Started Aug 2025; status: completed.
02
Drugs
BGM0504
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07166081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166081.